Genesis Biopharma and Lonza Partner form Partnership
News Jul 28, 2011
Genesis Biopharma, Inc., and Lonza have announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.
Contego™ is a ready-to-infuse cell therapy based on currently available therapies at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.
"We are pleased to have such an experienced bioprocess development and manufacturing partner as Lonza," stated Mr. Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.
"Lonza is pleased to be in partnership with Genesis Biopharma, and to bring expertise in large-scale autologous cell therapy production to the task of making Contego™ widely available to patients suffering from metastatic melanoma," said David Smith, Head of Therapeutic Cell Solutions at Lonza.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019